Lead Product(s) : MKP10241
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : George Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
MKP10241 Food Effect, Safety & Efficacy in Healthy & Obese Adults with or Without Diabetes
Details : MKP10241 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2025
Lead Product(s) : MKP10241
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : George Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sintilimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Mankind Pharma Inks Pact with Innovent for Immunotherapy Drug in India
Details : Under the agreement with Innovent, Mankind Pharma will have exclusive rights to register, import, market, sell, and distribute TYVYT (sintilimab) in India.
Product Name : Tyvyt
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 26, 2024
Lead Product(s) : Sintilimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Innovent Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Bharat Serums & Vaccines ltd
Deal Size : $1,637.3 million
Deal Type : Acquisition
Mankind Pharma Completes Landmark Acquisition of BSV
Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (carboprost tromethamine), which is indicated for the treatment of post partum haemorrhage.
Product Name : Endoprost
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 23, 2024
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Bharat Serums & Vaccines ltd
Deal Size : $1,637.3 million
Deal Type : Acquisition
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Recipient : Bharat Serums & Vaccines ltd
Deal Size : $1,640.0 million
Deal Type : Acquisition
India's Mankind Pharma to Buy Bharat Serums in a $1.6 Billion Deal
Details : Through the acquisition of BSV, Mankind will enhance its pipelines including Endoprost (Carboprost Tromethamine), which is indicated for the treatment of post partum haemorrhage.
Product Name : Endoprost
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 26, 2024
Lead Product(s) : Carboprost Tromethamine
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Recipient : Bharat Serums & Vaccines ltd
Deal Size : $1,640.0 million
Deal Type : Acquisition
Lead Product(s) : Vonoprazan Fumarate
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Recipient : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India
Details : Under the terms of this agreement, Takeda has granted Mankind Pharma non-exclusive patent licensing rights for the commercialization of Voquezna (vonoprazan) in India.
Product Name : Voquezna
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 16, 2024
Lead Product(s) : Vonoprazan Fumarate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Recipient : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Recipient : AstraZeneca
Deal Size : Undisclosed
Deal Type : Agreement
Mankind Pharma Enters Exclusive Pact to Distribute AstraZeneca's Symbicort in India
Details : Under the agreement, Mankind Pharma will distribute AstraZeneca's anti-asthma inhaled corticosteroid drug Symbicort, (budesonide/formoterol) approved to treat asthma and COPD, in India.
Product Name : Breztri Aerosphere
Product Type : Steroid
Upfront Cash : Undisclosed
March 13, 2024
Lead Product(s) : Budesonide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Recipient : AstraZeneca
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : S-Pindolol Benzoate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Recipient : Actimed Therapeutics
Deal Size : $6.3 million
Deal Type : Series A Financing
Details : The investment will support the development of the Actimed pipeline, including ACM-001.1 (S-pindolol benzoate), with preparations under way for a Phase 2b/3 programme targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorect...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 26, 2023
Lead Product(s) : S-Pindolol Benzoate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Recipient : Actimed Therapeutics
Deal Size : $6.3 million
Deal Type : Series A Financing
Lead Product(s) : Pindolol
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Recipient : Actimed Therapeutics
Deal Size : $12.1 million
Deal Type : Financing
Details : ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 04, 2023
Lead Product(s) : Pindolol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Recipient : Actimed Therapeutics
Deal Size : $12.1 million
Deal Type : Financing
Lead Product(s) : Formoterol Fumarate,Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Recipient : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Acquisition
Mankind Pharma to Acquire Combihale and Daffy Brands From Dr Reddy's Laboratories
Details : The acquisition of “Combihale” is expected to strengthen Mankind’s presence in the inhalation respiratory market segment. Daffy is a soap-free moisturising bar for infant babies.
Product Name : Combihale
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 16, 2022
Lead Product(s) : Formoterol Fumarate,Fluticasone Propionate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Recipient : Dr. Reddy\'s Laboratories
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Tacrolimus
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Panacea Biotec Limited
Deal Size : $251.1 million
Deal Type : Agreement
Panacea Biotec Sells Domestic Formulation Assets To Mankind Pharma for Rs 1,908 Crore
Details : The top selling brands are Pangraf (tacrolimus), Alphadol (alfacalcidol), Cilamin (penicillamine) & Livoluk Fibre (lactulose in combination with ispaghula) were ranked number 1, whereas Glizid (Gliclazide + Metformin), Mycept (Mycophenolate Mofetil) were...
Product Name : Pangraf
Product Type : Antibiotic
Upfront Cash : Undisclosed
February 01, 2022
Lead Product(s) : Tacrolimus
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Panacea Biotec Limited
Deal Size : $251.1 million
Deal Type : Agreement
KEY PRODUCTS
Reset All
Delivering quality and niche Active Pharmaceutical Ingredients across the global from our USFDA-approved facility.
